Pfizer (PFE) : Ancora Advisors reduced its stake in Pfizer by 0.48% during the most recent quarter end. The investment management company now holds a total of 184,171 shares of Pfizer which is valued at $6,442,302 after selling 890 shares in Pfizer , the firm said in a disclosure report filed with the SEC on Aug 11, 2016.Pfizer makes up approximately 0.73% of Ancora Advisors’s portfolio.
Other Hedge Funds, Including , Tredje Ap-fonden reduced its stake in PFE by selling 68,172 shares or 7.92% in the most recent quarter. The Hedge Fund company now holds 793,111 shares of PFE which is valued at $27,743,023. Pfizer makes up approx 1.15% of Tredje Ap-fonden’s portfolio.Cornerstone Capital reduced its stake in PFE by selling 2,950 shares or 21.27% in the most recent quarter. The Hedge Fund company now holds 10,920 shares of PFE which is valued at $381,982. Pfizer makes up approx 0.08% of Cornerstone Capital’s portfolio.Smead Capital Management reduced its stake in PFE by selling 148,558 shares or 5.79% in the most recent quarter. The Hedge Fund company now holds 2,417,868 shares of PFE which is valued at $85,689,242. Pfizer makes up approx 3.86% of Smead Capital Management’s portfolio.Cadence Capital Management reduced its stake in PFE by selling 59,911 shares or 15.58% in the most recent quarter. The Hedge Fund company now holds 324,604 shares of PFE which is valued at $11,455,275. Pfizer makes up approx 0.83% of Cadence Capital Management’s portfolio. Obermeyer Wood Investment Counsel Lllp added PFE to its portfolio by purchasing 6,667 company shares during the most recent quarter which is valued at $235,278. Pfizer makes up approx 0.02% of Obermeyer Wood Investment Counsel Lllp’s portfolio.
Pfizer opened for trading at $35 and hit $35.27 on the upside on Tuesday, eventually ending the session at $35.09, with a gain of 0.72% or 0.25 points. The heightened volatility saw the trading volume jump to 1,69,57,889 shares. Company has a market cap of $212,844 M.
On the company’s financial health, Pfizer reported $0.64 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Aug 2, 2016. Analyst had a consensus of $0.62. The company had revenue of $13147.00 million for the quarter, compared to analysts expectations of $13013.24 million. The company’s revenue was up 10.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.56 EPS.
Many Wall Street Analysts have commented on Pfizer. Shares were Reiterated by Jefferies on Jun 20, 2016 to “Buy” and Lowered the Price Target to $ 40 from a previous price target of $42 .
Pfizer Inc. is a global biopharmaceutical company. The Company is engaged in discovering developing and manufacturing of healthcare products. Its products include Lyrica the Prevnar family of products Enbrel Celebrex Lipitor Viagra Zyvox Sutent EpiPen Toviaz Tygacil Rapamune Xalkori Inlyta Norvasc BeneFIX Genotropin and Enbrel among others. It operates in three segments: Global Innovative Pharmaceutical segment (GIP) Global Vaccines Oncology and Consumer Healthcare segment (VOC) and Global Established Pharmaceutical segment (GEP). GIP is focused on developing registering and commercializing medications in therapeutic areas such as inflammation cardiovascular/metabolic neuroscience and pain rare diseases and women’s/men’s health. VOC focuses on the development and commercialization of vaccines and products for oncology and consumer healthcare. GEP includes its sterile injectable products and bio similar development portfolio. Its subsidiary is Hospira Inc.